These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35880850)

  • 1. Developing evolution-resistant drugs for COVID-19.
    Weinreich DM
    Elife; 2022 Jul; 11():. PubMed ID: 35880850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico evaluation of Philippine Natural Products against SARS-CoV-2 Main Protease.
    Cheng AJT; Macalino SJY; Billones JB; Balolong MP; Murao LAE; Carrillo MCO
    J Mol Model; 2022 Oct; 28(11):345. PubMed ID: 36205801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent inhibitors of SARS-CoV-2 3C-like protease derived from N-substituted isatin compounds.
    Liu P; Liu H; Sun Q; Liang H; Li C; Deng X; Liu Y; Lai L
    Eur J Med Chem; 2020 Nov; 206():112702. PubMed ID: 32798789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.
    Kandeel M; Al-Nazawi M
    Life Sci; 2020 Jun; 251():117627. PubMed ID: 32251634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives.
    La Monica G; Bono A; Lauria A; Martorana A
    J Med Chem; 2022 Oct; 65(19):12500-12534. PubMed ID: 36169610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
    Martorana A; Gentile C; Lauria A
    Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AI-Aided Design of Novel Targeted Covalent Inhibitors against SARS-CoV-2.
    Tang B; He F; Liu D; He F; Wu T; Fang M; Niu Z; Wu Z; Xu D
    Biomolecules; 2022 May; 12(6):. PubMed ID: 35740872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.
    Fintelman-Rodrigues N; Sacramento CQ; Ribeiro Lima C; Souza da Silva F; Ferreira AC; Mattos M; de Freitas CS; Cardoso Soares V; da Silva Gomes Dias S; Temerozo JR; Miranda MD; Matos AR; Bozza FA; Carels N; Alves CR; Siqueira MM; Bozza PT; Souza TML
    Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32759267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress of SARS-CoV-2 Main protease peptide-like inhibitors.
    Liu X; Ren X; Hua M; Liu F; Ren X; Sui C; Li Q; Luo F; Jiang Z; Xia Z; Chen J; Yang B
    Chem Biol Drug Des; 2024 Jan; 103(1):e14425. PubMed ID: 38082476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
    Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A
    Molecules; 2020 May; 25(11):. PubMed ID: 32485894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luminescent Assay for the Screening of SARS-CoV-2 M
    Sondag D; Merx J; Rossing E; Boltje TJ; Löwik DWPM; Nelissen FHT; van Geffen M; van 't Veer C; van Heerde WL; Rutjes FPJT
    Chembiochem; 2022 Aug; 23(15):e202200190. PubMed ID: 35649961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting allosteric pockets of SARS-CoV-2 main protease M
    Bhat ZA; Chitara D; Iqbal J; Sanjeev BS; Madhumalar A
    J Biomol Struct Dyn; 2022 Sep; 40(14):6603-6618. PubMed ID: 33645457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated bioinformatics-cheminformatics approach toward locating pseudo-potential antiviral marine alkaloids against SARS-CoV-2-Mpro.
    Swain SS; Singh SR; Sahoo A; Panda PK; Hussain T; Pati S
    Proteins; 2022 Sep; 90(9):1617-1633. PubMed ID: 35384056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors.
    Jo S; Signorile L; Kim S; Kim MS; Huertas O; Insa R; Reig N; Shin DH
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach.
    Biembengut ÍV; de Souza TACB
    Mem Inst Oswaldo Cruz; 2020; 115():e200179. PubMed ID: 32490889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of alliin as a putative inhibitor of the main protease of SARS-CoV-2 by molecular docking.
    Cheng B; Li T
    Biotechniques; 2020 Aug; 69(2):108-112. PubMed ID: 32459144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depicting the inhibitory potential of polyphenols from
    Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
    J Biomol Struct Dyn; 2022 Jun; 40(9):4110-4121. PubMed ID: 33292085
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Umadevi P; Manivannan S; Fayad AM; Shelvy S
    J Biomol Struct Dyn; 2022 Jul; 40(11):5053-5059. PubMed ID: 33372574
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.